Clinical Trial Update: A Study of the Efficacy and Safety of ABH001 in the Treatment of Patients With Epidermolysis Bullosa Who Have Wounds That Are Not Healing [Phase 3]

View source ↗

Summary

A Phase 3 trial evaluating ABH001 for non-healing wounds in epidermolysis bullosa has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Epidermolysis Bullosa

Drugs mentioned

• ABH001

Snippet

Sponsor: Shire Regenerative Medicine, Inc. | Conditions: Epidermolysis Bullosa | Phase 3 | Status: TERMINATED